Just looked into what Bill Gates actually owns in his foundation's portfolio and it's pretty telling about where he thinks the future is heading.

So Gates sits on $130 billion in wealth, and here's the thing - he's put roughly 35% of the Gates Foundation's money into just two AI-focused plays. That's a serious concentration bet on artificial intelligence.

The obvious one is Microsoft. Almost 34% of the foundation's portfolio is in MSFT, which honestly isn't surprising given Gates literally co-founded the company and ran it for 25 years. But what's interesting is why he's doubling down now - Microsoft's entire recent growth story revolves around AI. They've baked OpenAI's GPT-4 throughout everything: Azure cloud platform, Windows OS, Microsoft 365, GitHub Copilot. The platform is everywhere. Over half of Fortune 500 companies are already using Azure AI according to recent reports. That kind of adoption rate is hard to ignore.

The second holding caught my attention more though - Schrödinger. Less than 0.6% of the portfolio in dollar terms, but it gives the Gates Foundation over 11% ownership, making them the second-largest shareholder. Officially Schrödinger calls itself a drug development and materials science software company, which is technically true. But really? They're using machine learning to predict molecular structures and accelerate drug discovery. They've got partnerships with major pharma like Bristol Myers Squibb and Eli Lilly, plus smaller biotech shops. Two proprietary drug candidates in early clinical testing already.

Now here's where it gets real - are these no-brainer buys just because Gates owns them? Not really. Microsoft trades at over 31x forward earnings, which is premium territory. Schrödinger isn't even profitable yet and sits at a 9.2x price-to-sales multiple. Wall Street's bullish (27 out of 34 analysts rate Microsoft as buy/strong buy, Schrödinger's consensus target is 45% above current price), but that doesn't mean the valuations make sense at these levels.

Microsoft feels like a solid long-term hold if you believe in AI's staying power - which honestly, seems like a safe bet. Schrödinger though? I'd want to see how their drug candidates actually perform in later-stage testing before jumping in. Sometimes what billionaires own tells you about direction, but not always about timing.